Ginkgo Bioworks (DNA) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed ProKidney (PROK) over the past year, losing 29.5% versus a loss of 49.1%. Over five years, PROK leads with a -83.2% price change compared with -97.6% for DNA. Ginkgo Bioworks is the larger company by market cap ($876.1 million vs $694.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | PROK |
|---|---|---|
| Share price | $13.01 | $1.74 |
| Market cap | $876.10M | $694.58M |
| 1-day change | +14.73% | +4.82% |
| YTD return | +36.46% | -25.89% |
| 1-year return | -29.52% | -49.08% |
| 5-year return | -97.62% | -83.18% |
| EPS (TTM) | $-5.06 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $3.48 |
| 52-week low | $5.37 | $1.30 |
| Distance from 52-week high | -28.59% | -50.00% |
| Analyst consensus | none | none |
| Avg. price target upside | -46.20% | +259.20% |
| Average volume | 1.80M | 1.30M |
| Shares outstanding | 55.38M | 208.93M |
| Employees | 485 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNA has outperformed PROK by 19.6 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
DNA vs PROK FAQ
Which is bigger, Ginkgo Bioworks or ProKidney?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $876.10M compared with $694.58M for ProKidney (PROK).
Which stock has performed better over the past year, DNA or PROK?
DNA returned -29.52% over the past 12 months, compared with -49.08% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.